---
title: "Varegacestat (AL102) in Desmoid tumors: Dosage"
description: "Formulary evidence on Varegacestat (AL102, BMS-986115) in Desmoid tumors: Dosage. Topics: Randomized dose and open-label extension dose, Dose selection for the RINGSIDE phase III trial, Dose reduction levels and time to first dose modification, and Dose levels and dose modification rules for BMS-986115. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description/dosage"
published: "2026-11-18T22:42:04-05:00"
modified: "2026-11-18T22:42:04-05:00"
---

# Varegacestat (AL102) in Desmoid tumors: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Randomized dose and open-label extension dose

> “Participants in the study were randomized 1:1 and received either 1.2 mg varegacestat or placebo given once daily.”
> “Participants who progress while on study are eligible to enter an open-label extension whereby they may receive varegacestat at a dose of 1.2 mg once daily until disease progression or unacceptable toxicity.”

Source: [Immunome Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088172/imnm-20251231.htm)

<a id="topic-2.1.2.10.1-2"></a>

### Dose selection for the RINGSIDE phase III trial

> “Participants were randomly assigned 1:1:1 to oral varegacestat 1.2-mg once-daily, 2-mg intermittent (once daily for 2 consecutive days with 5 consecutive days off), or 4-mg intermittent dose.”
> “The largest responses were seen with the 1.2-mg once-daily dose, which was selected for the RINGSIDE phase III trial.”

Source: [Chugh et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-26-00725)

> “Overall, the ER analyses for efficacy and safety support 1.2 mg QD as the recommended dose.”

Source: [Fetterly et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File_4_ESMO-2026_VAR-ER_Poster_Final.pdf)

<a id="topic-2.1.2.10.1-3"></a>

### Dose reduction levels and time to first dose modification

> “Median Time to First Dose Reduction”
> “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months”
> “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months”
> “Median Time to First Dose Interruption”
> “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months”
> “Time to dose reduction or dose interruption is defined as the duration from the date of the first dose to the start date of the first dose reduction (to either dose) or dose interruption.”
> “Dose Reduction”
> “Varegacestat 80% | Placebo 9%”
> “Dose Interruption”
> “Varegacestat 65% | Placebo 14%”

Source: [Rutkowski et al. (2026)](https://immunome.com/wp-content/uploads/2026/10/File-2_ESMO-2026_RINGSIDE-B_AE_POS_final.pdf)

<a id="topic-2.1.2.10.1-4"></a>

### Dose levels and dose modification rules for BMS-986115

> “BMS-986115 was administered orally once daily (QD) at doses of 0.3, 0.6, 1.2, 1.5, and 2 mg (Arm A) or twice weekly (BIW) on consecutive days at doses of 2, 4, 8 mg (Arm B).”
> “Dose interruption (up to 28 days) and/or dose modification (up to 2 dose reductions) were permitted in the event of study drug toxicity.”

Source: [Aung et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7523345/)

## Related pages
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors.md)
- [Varegacestat (AL102) in Desmoid tumors: Terms and abbreviations](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/terms-and-abbreviations.md)
- [Varegacestat (AL102): Desmoid tumors](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/executive-summary.md)
- [Varegacestat (AL102) in Desmoid tumors: Product information and disease description](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/product-information-and-disease-description.md)
- [Varegacestat (AL102) in Desmoid tumors: Clinical evidence](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/clinical-evidence.md)
- [Varegacestat (AL102) in Desmoid tumors: Economic information and modeling report](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/economics.md)
- [Varegacestat (AL102) in Desmoid tumors: References](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references) · [Markdown](https://www.evicenter.com/drugs/varegacestat--desmoid-tumors/references.md)
